single dose Johnson & Johnson's Covid vaccine has shown strong neutralising antibody activity against the Delta (B16172) variant, with immunity lasting at least eight months, according to results of phase-III trials.
Submitted to pre-print of bioRxiv, the phase-III trials showed the vaccine was consistently effective across all regions studied globally, including in South Africa and Brazil, where there was a high prevalence of rapidly emerging Beta and Zeta (P2) variants during the study period.
It also generated neutralising antibodies against a range of other SARS-CoV-2 variants of concern, which increased over time, such as the Gamma (P1) variants and the Alpha (B117), Epsilon (B1429), Kappa (B16171), and D614G variants, as well as the original SARS-CoV-2 strain.
“Today's newly announced studies reinforce the ability of the Johnson & Johnson Covid-19 vaccine to help protect the health of people globally,” said Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson, in a statement here.